Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1997-09-22
2000-01-11
Saunders, David
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241441, 4241541, 514 9, 514 26, 5303873, 53038822, 53038875, 530317, 552576, A61K 39395, A61K 3813, A01N 4500, C07J 600
Patent
active
060132566
ABSTRACT:
The invention provides methods of preventing acute rejection following renal or other solid organ transplantation. The methods entail administering, e.g., intravenously, to a transplant patient a monoclonal antibody which binds to the p55 subunit of the human interleukin-2 (IL-2) receptor of human T lymphocytes. The monoclonal antibody is preferably a chimeric or humanized antibody that blocks binding of IL-2 to the IL-2 receptor. In some methods, a single dose of about 1 mg/kg of antibody is administered about every other week, commencing immediately prior to transplantation and continuing until 8 weeks after transplantation.
REFERENCES:
patent: 5011684 (1991-04-01), Strom
patent: 5084391 (1992-01-01), Wijdenes et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
Gaber, AO et al. Am. Surg. 53(7): 407-409, Jul. 1987.
Delmonico, FL et al. Annals of Surgery. 206(5):549-654, Nov. 1987.
Nashan et al., "Reduction of acute cellular rejection by basiliximab (SIMULECT.TM.), in renal allograft recipients," American Society of Transplant Surgeons, Presented at 23.sup.rd Annual Scientific Meeting (May 14-16, 1997).
Transplantation Proceedings, Second International Congress on Cyclosporine, OLXX, No. 2. Supp, pp. 203-206 (1988).
"Delayed Allograft Rejection In Primates Treated With Anti-il-2 Receptor Monoclonal Antibody Campath-6" Transplantation 45(1):226-228 (1988).
Bone Marrow Transplantation, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Abstract Book, DAVOS Switzerland, Mar. 19-23, 1995, vol. 15, Supplement 2 (1995).
Journal of the American Society of Hematology, Thirty-Seventh Annual Meeting, Dec. 1-5, 1995 Seattle, WA, Blood, vol. 86, No. 10 Supplement 1 (1995).
Anasetti et al. "Treatment of Acute Graft-Versus-Host Disease with Humanized Anti-Tac: An Antibody That Binds to the Interleukin-2 Receptor" Blood, 84(4):1320-1327 (1994).
Brown, Jr., P.S. et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs the primate cardiac allograft survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (Apr. 1991).
Carpenter, C.B. et al., "Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation" Am. J. Kidney Diseases XIV(5), Suppl. 2:54-57 (Nov. 1989).
Hakimi, J. et al., "Humanized Mik.beta.1, A humanized antibody to the IL-2 Receptor .beta.-chain that acts synergistically with humanized anti-TAC" J. Immunol. 151(2):1075-1085 (Jul. 1993).
Herve et al. Treatment of Corticosteriod Resistant Acute Graft-Versus Disease by In Vivo Administration of Anti-Interleukin-2 Receptor Monoclonal Antibody (B-B10), Blood, 75(4):1017-1023 (1990).
Junghans, R.P. et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders" Cancer Res. 50:1495-1502 (Mar. 1990).
Kirkman, R.L. et al., "Early experience with anti-Tac in clinical renal transplantation" Transplantation Proc. 21(1):1766-1768 (Feb. 1989).
Kirkman, R.L. et al., "A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation" Transplantation 51(1):107-113 (Jan. 1991).
Kupiec-Weglinski, H.J. et al., "Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy" Transplantation Proc. XX, No. 2, Suppl. 2:207-216 (Apr. 1988).
Kupiec-Weglinski et al., "Interleukin 2 Receptor-Targeted Therapy-Rationale and Applications in Organ Transplantation" Transplantation 46(6):785-792 (1988).
Nashan et al., "Immunoprophylaxis with a Monoclonal Anti-IL-2 Receptor Antibody in Liver Transplant Patients" Transplantation 61(4):546-554 (1996).
Queen et al. "A Humanized Antibody That Binds to the Interleukin 2 Receptor" Proc. Natl. Acad. Sci 86:10029-10033 (1989).
Reed, M.H. et al., "Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody" Transplantation 47(1):55-59 (Jan. 1989).
Rose et al. "A Chimeric Mouse/Human Anti-IL-2 Receptor Antibody With Enhanced Biological Activities" Molecular Immunology 29(1):131-144 (1992).
Rose et al. "Differential Effects of a Murine and Chimeric Mouse/Human Anti-Interleukin-2 Receptor Antibody on Human T-Cell Proliferation" Immunology 76:452-459 (1992).
Soulillou et al. "Prevention of Rejection of Kidney Transplants by Monoclonal Antibody Directed Against Interleukin 2" The LANCET, pp. 1339-1342 (1987).
Soulillou et al. "Randomized Controlled Trail of a Monoclonal Antibody Against The Interleukin-2 Receptor (33B3.1) As Compared with Rabbit Antithymocyte Globulin For Prophylaxis Against Rejection of Renal Allografts" The New England Journal of Medicine 322(17):1175-1182 (1990).
Soulillou et al. "Monoclonal Anti-IL2-Receptor in Organ Transplantation" Transplant Int 2:46-52 (1989).
Strom et al. "Toward More Selective Therapies to Block Undesired Immune Responses" Kidney International, 35:1026-1033 (1989).
Ueda et al., "Differential Effects of Interleukin 2 Receptor-Targeted Therapy on Heart and Kidney Allografts in Rats" Transplantation 49(6):1124-1129 (1990).
Waldmann, T.A., "The IL-2/IL-2 receptor system: A target for rational immune intervention" Immunol. Today 14(6):264-270 (1993).
Waldmann et al., "The Multichain Interleukin-2 Receptor: A Target for Immunotherapy of Patients Receiving Allografts" American Journal of Kidney Diseases XIV(5) Suppl 2, 45-53 (1989).
Waldmann et al., "Lymphokine Receptor-Directed Therapy: A Model of Immune Intervention" Journal of Clinical Immunology 10(6): 19S-29S (1990).
Vincenti, et al., Proc. 14th Annual Meeting of the Amer. Soc. of Transplant Physicians, Chicago, IL, May 14-17, 1995, p. 90 (abstract 68).
Bickel et al., "Differential Regulation Of Colony-Stimulating Factors And Interleukin 2 Production By Cyclosporin A", Proc. Natl. Acad. Sci. USA, 84(10):3274-3277 (1987).
Clipstone et al., "Identification Of Calcineurin As A Key Signalling Enzyme In T-Lymphocyte Activation", Nature, 357(6380):695-697 (1992).
Depper et al., "Blockade Of The Interleukin-2 Receptor By Anti-Tac Antibody: Inhibition Of Human Lymphocyte Activation", J. Immunol., 131(2):690-696 (1983).
Kirkman et al., "Administration Of An Anti-Interleukin 2 Receptor Monoclonal Antibody Prolongs Cardiac Allograft Survival In Mice", J. Exp. Med., 162(1):358-362 (1985).
Kovarik et al., "Disposition Of Basiliximab, An Interleukin-2 Receptor Monoclonal Antibody, In Recipients Of Mismatched Cadaver Renal Allografts", Transplantation, 64(12):1701-1705 (1997).
Nashan et al., "Randomised Trial Of Basiliximab Versus Placebo For Control Of Acute Cellular Rejection In Renal Allograft Recipients", Lancet, 350(9086):1193-1198 (1997).
Schreiber et al., "The Mechanism Of Action Of Cyclosporin A And FK506", Immunol. Today, 13(4):136-142 (1992).
Shapiro et al., "Monoclonal Anti-IL-2 Receptor Antibody In Primate Renal Transplantation", Transplant. Proc., 19(1 Pt. 1):594-598 (1987).
Vincenti et al., "A Phase I Trial Of Humanized Anti-Interleukin 2 Receptor Antibody In Renal Transplantation", Transplantation, 63(1):33-38 (1997).
Physicians' Desk Reference, 52nd Edition, 1998, pp. 1971-1974.
Zlabinger et al., "Cytokine Release And Dynamics Of Leukocyte Populations After CD3/TCR Monoclonal Antibody Treatment", J. Clin. Immunol., 12(3):170-177 (1992).
Light Susan
Queen Cary
Protein Design Labs, Inc.
Saunders David
VanderVegt F. Pierre
LandOfFree
Method of preventing acute rejection following solid organ trans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing acute rejection following solid organ trans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing acute rejection following solid organ trans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459828